Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Avi Kapoor

This Actuate Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday

Analyst,Works,On,Personal,Computer,Showing,Business,Analytics,Dashboard,With

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • B. Riley Securities analyst Mayank Mamtani initiated coverage on Actuate Therapeutics, Inc. (NASDAQ:ACTU) with a Buy rating and announced a price target of $20. Actuate Therapeutics shares closed at $7.98 on Monday. See how other analysts view this stock.
  • HC Wainwright & Co. analyst Matthew Keller initiated coverage on Gyre Therapeutics, Inc. (NASDAQ:GYRE) with a Buy rating and announced a price target of $18. Gyre Therapeutics shares closed at $8.18 on Monday. See how other analysts view this stock.
  • William Blair analyst Andrew Brackmann initiated coverage on CareDx, Inc (NASDAQ:CDNA) with a Market Perform rating. CareDx shares closed at $12.75 on Monday. See how other analysts view this stock.

Considering buying ACTU stock? Here’s what analysts think:

Read This Next:

Photo via Shutterstock

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.